Stock listing
475830 Stock Price, News, Filings & Events — Orum Therapeutics, Inc.
Selected listing: 475830 · KRX · KRW · KR
This page tracks Orum Therapeutics, Inc.'s 475830:KRX listing on KRX in KRW for KR, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following 475830:KRX. 475830:KRX is the stock-level entry point for investors researching Orum Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Orum Therapeutics, Inc. is a public company traded under the ticker 475830 on the Korean market. The company has a market capitalization of approximately 698.3 billion KRW. Orum Therapeutics focuses on developing innovative therapeutic solutions in the biotechnology sector.

- Ticker
- 475830:KRX
- Asset type
- Stock
- Market cap
- $888.1M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- KRX
- Currency
- KRW
Orum Therapeutics, Inc. 475830:KRX stock context
This page tracks Orum Therapeutics, Inc.'s 475830:KRX listing on KRX in KRW for KR, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following 475830:KRX. 475830:KRX is the stock-level entry point for investors researching Orum Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Orum Therapeutics, Inc. is a public company traded under the ticker 475830 on the Korean market. The company has a market capitalization of approximately 698.3 billion KRW. Orum Therapeutics focuses on developing innovative therapeutic solutions in the biotechnology sector.
Latest news from Orum Therapeutics, Inc.
Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate
August 22, 2026
Orum Therapeutics Appoints Dr. Maria Koehler and Geoff Meyerson to Board of Directors
April 13, 2026
Orum Therapeutics to Present New Preclinical Data on ORM-1153, a CD123-Targeting Degrader Antibody Conjugate, at the AACR Annual Meeting ...
March 17, 2026
Orum Therapeutics Announces Presentation of Preclinical Data for ORM-1153 at the 2025 American Society of Hematology (ASH) Annual Meeting
November 3, 2025
Orum Therapeutics Appoints Dr. Dorin Toader as Head of Platform Technology to Advance Orum’s Degrader–Antibody Conjugate Payload Platform...
October 14, 2025
Research Orum Therapeutics, Inc.
Orum Therapeutics, Inc. investor report
Review AI stock analysis and investor report context for 475830:KRX.
Orum Therapeutics, Inc. company profile
View the public company page for Orum Therapeutics, Inc. on 6ix.
Orum Therapeutics, Inc. news
Read company news and market updates connected to Orum Therapeutics, Inc..
Orum Therapeutics, Inc. investor events
Find investor webinars, events, and replay context for Orum Therapeutics, Inc..